Trials / Completed
CompletedNCT00995709
Phase III Study in Refractory Behcet's Disease
A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AIN457 | |
| DRUG | AIN457 | |
| DRUG | Placebo |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2009-10-15
- Last updated
- 2015-08-31
- Results posted
- 2015-08-31
Locations
49 sites across 17 countries: United States, Egypt, France, Germany, Greece, Hong Kong, India, Israel, Italy, Jordan, Singapore, South Korea, Spain, Switzerland, Taiwan, Tunisia, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00995709. Inclusion in this directory is not an endorsement.